Webinar: Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice
Our webinar “Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice” was live on March 16, 2022 at 11AM EDT.…
Read more
Immuno-Oncology 360° 2022 Summit
IO360˚convenes stakeholders from the science and business communities to report on the latest data impacting IO to fight a wider range of cancers.
Read more
Festival of Biologics USA 2022
Speaker: Li Hui M.D., Ph.D., Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston Corp Time: 5:10pm PST, March 9th Talk title: Streamlining Therapeutic Antibody Discovery…
Read more
Webinar: Mouse Models to Investigate New Treatments for Inflammatory Disease
We’re pleased to continue our new webinar series informing and updating our network of research professionals. We invite you to join us to learn about…
Read more
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase II Clinical Trial of YH003 in Australia
Beijing, China, December 9, 2021/PRNewswire/ – Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase II clinical trial…
Read more
2021 Highlights: Humanized Model Publications
We are proud to highlight our growing list of publications featuring off-the-shelf and customized mouse, rat, and cancer cell models in well-respected, high-impact journals. Featured below…
Read more
Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase I Clinical Trial of YH004 (Anti-4-1BB Monoclonal Antibody) in Australia
BEIJING, CHINA, December 7, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of…
Read more
Biocytogen/Eucure Biopharma’s YH001 (Anti-CTLA-4 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration
BEIJING, November 9, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration…
Read more
Webinar: Investigating Inflammatory Disease using Humanized Cytokine Mice
Our webinar “Investigating Inflammatory Disease using Humanized Cytokine Mice” was live on Dec 1, 2021 at 1PM. In this webinar, we will: - Review the…
Read more
Biocytogen/Eucure Biopharma’s YH003 (Anti-CD40 Monoclonal Antibody) Approved for Phase II Multi-Regional Clinical Trial by China National Medical Products Administration
BEIJING, November 2, 2021 - Eucure Biopharma, a wholly owned subsidiary of Biocytogen dedicated to developing proprietary antibody drugs, announced that the China National Medical Products Administration…
Read more